Status:
UNKNOWN
Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation
Lead Sponsor:
University Health Network, Toronto
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Liver transplantation is the standard treatment for patients with early-stage Hepatocellular Carcinoma (HCC). Currently, important treatment decisions, like the selection of patients for transplantati...
Detailed Description
Hepatocellular Carcinoma (HCC) is the third leading cause of death by cancer worldwide, being responsible for nearly 700,000 deaths in 2012. Liver transplantation (LT) provides the best results as a c...
Eligibility Criteria
Inclusion
- Histological or radiological diagnosis of HCC (AASLD guidelines)
- Listed for LT at UHN
- Enrolled in ctDNA study (15-5925)
- Able to undergo PET and MRI examination,
- Willingness and ability of patient to provide signed voluntary informed consent.
- Adults (age ≥ 18-years old)
Exclusion
- Any contraindication to undergoing venipuncture.
- Patients with previous history of cancer diagnosed and/or treated within last 5 years, with the exception of non-melanomatous skin cancers and intraepithelial cancers such as cervical intraepithelial neoplasia that were properly treated, are not eligible.
- Inability to lie supine for at least 30 minutes.
Key Trial Info
Start Date :
August 22 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03839706
Start Date
August 22 2018
End Date
September 1 2024
Last Update
December 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2N2